+65 3158 9940
1300 798 820
+64 9801 0299
Singapore 11 June 2025: Independent biopharmaceutical company Specialised Therapeutics (ST) is pleased to announce the expansion of its existing supply and distribution agreement with Incyte Biosciences International Sàrl, the Swiss-based affiliate of Incyte (NASDAQ:INCY), to launch and distribute two additional medicines from its oncology portfolio in Australia, New Zealand and Singapore, with an option to add
SKYTROFA® ® (lonapegsomatropin) is now registered by the Therapeutic Goods Administration (TGA) for the treatment of paediatric growth hormone deficiency.1 Singapore 30 May 2025: Independent biopharmaceutical company Specialised Therapeutics (ST) is pleased to announce the Australian registration of SKYTROFA® (lonapegsomatropin) as a new once-weekly injectable therapy for paediatric growth hormone deficiency (GHD).2 The Therapeutic Goods
YORVIPATH® (palopegteriparatide) is now registered by the Therapeutic Goods Administration (TGA) for the treatment of chronic hypoparathyroidism in adults1 First-in-class novel PTH replacement therapy Australia becomes the first country to obtain Marketing Authorisation for YORVIPATH since FDA approval Singapore 21 February 2025: Independent biopharmaceutical company Specialised Therapeutics (ST) welcomes the registration of YORVIPATH® (palopegteriparatide) by
ST has featured in the latest MedTech Sector report published by financial services and corporate advisory firm RSM. Turn to pages 16 and 17 where CEO Carlo Montagner discusses our business model, licensing strategy and future plans. Click on the magazine below to read the article.
ST has featured in the latest MedTech Sector report published by financial services and corporate advisory firm RSM. Turn to pages 16 and 17 where CEO Carlo Montagner discusses our business model, licensing strategy and future plans. Click on the magazine below to read the article.
Agreement between Ascendis Pharma A/S and ST is for the exclusive distribution and commercialisation of three Ascendis Pharma endocrinology therapies Two of the therapies are already internationally approved, the third is in development following successful Phase 2 data ST’s exclusive distribution agreement covers Australia, New Zealand, Singapore, Malaysia, Brunei, Thailand and Vietnam Singapore 8 January
57 year old Lay Har has never been a smoker and has always considered herself relatively healthy, was shocked when she was diagnosed with Stage 4 Small Cell Lung Cancer in April this year, after experiencing some “discomfort” in her chest. She was scared by her diagnosis but has found support from fellow patients and
First ovarian cancer therapy for ST oncology portfolio Phase 2 study demonstrated oregovomab in combination with chemotherapy improved progression free survival by ~30 months compared to chemotherapy alone1 Phase 3 results expected in 2025 Exclusive license for AU, NZ, Singapore, Malaysia, Brunei, Thailand and Vietnam Singapore and Seoul, South Korea, 13 October 2023: Independent
Consultant Clinical Oncologist Dr Aqilah Othman says an ageing population, fewer and later pregnancies, a lack of physical activity, obesity and poor dietary habits may be contributing to a rising incidence of new breast cancer cases across Southeast Asia. To mark Breast Cancer Awareness Month 2023, the Sunway Medical Centre oncologist discusses the incidence of
SEA’s largest independent specialty pharma company Specialised Therapeutics (ST) has joined global pharma consortium committed to collaborating to provide new specialist medicines for rare diseases ST to represent WODA in Australia, New Zealand and across Southeast Asia (ANZSEA) World Orphan Drug Alliance (WODA) now spans 152 countries. WODA offers a ‘one-stop’ solution for biotech companies